Printer Friendly

AGOURON PHARMACEUTICALS BEGINS CLINICAL TESTING OF PSORIASIS DRUG

AGOURON PHARMACEUTICALS BEGINS CLINICAL TESTING OF PSORIASIS DRUG
 SAN DIEGO, Dec. 2 /PRNewswire/ -- Agouron Pharmaceuticals Inc. (NASDAQ-NMS: AGPH) announced today that clinical testing has been initiated for a new, rationally designed drug for topical treatment of psoriasis. The clinical study initiated at the Skin Research Foundation of California in Los Angeles was authorized by the Food and Drug Administration in November. It will evaluate the therapeutic potential of the Agouron drug designated AG-85 in a small number of psoriasis patients. The company expects to have results of this initial clinical study early in 1992.
 According to estimates by the National Psoriasis Foundation, 4 million Americans suffer from psoriasis -- a disease characterized by red, scaly lesions of hyper-proliferating skin cells. Using a technology known as protein structure-based drug design, Agouron scientists designed the synthetic chemical compound AG-85 to halt the abnormal proliferation of skin cells in psoriasis by inactivating a key enzyme known as thymidylate synthase (TS).
 Agouron Pharmaceuticals Inc. is a pioneer and leader in a new technology for the rational design of novel synthetic drugs based upon the molecular structures of proteins which play key roles in human disease. Agouron is currently applying this technology to the design and development of drugs for treatment of cancer, AIDS and other serious diseases.
 -0- 12/2/91
 /CONTACT: Peter Johnson, president and CEO, or Donna Nichols of Agouron Pharmaceuticals, 619-622-3000/
 (AGPH) CO: Agouron Pharmaceuticals Inc. ST: California IN: MTC SU: PDT


CH-AL -- SD004 -- 8212 12/02/91 09:04 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 2, 1991
Words:249
Previous Article:ALAN FREED TO BE AWARDED POSTHUMOUS STAR ON WALK OF FAME
Next Article:FURON ANNOUNCES THIRD QUARTER RESULTS
Topics:


Related Articles
AGOURON PHARMACEUTICALS CLEARED TO COMMENCE CLINICAL TESTING OF PSORIASIS DRUG
AGOURON PHARMACEUTICALS ANNOUNCES START OF HUMAN CLINICAL TRIALS FOR NEW ANTI-TUMOR AGENT
FDA CLEARS AGOURON PHARMACEUTICALS TO COMMENCE SECOND CLINICAL STUDY OF PSORIASIS DRUG
FDA AUTHORIZES CLINICAL TESTING OF SECOND AGOURON ANTI-TUMOR DRUG
AGOURON SUSPENDS DEVELOPMENT OF PSORIASIS AGENT
AGOURON PRESENTS PRECLINICAL DATA AT INTERNATIONAL CONFERENCE ON AIDS
AGOURON PRESENTS PRECLINICAL DATA AT INTERNATIONAL CONFERENCE ON AIDS
SAN DIEGO CENTERS BEGIN CLINICAL TESTING OF AGOURON ANTI-TUMOR DRUG AG337
METROHEALTH MEDICAL CENTER TO BEGIN CLINICAL TESTING OF AGOURON ANTI-TUMOR DRUG AG337

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters